{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T01:34:15Z","timestamp":1771983255310,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.urolonc.2023.03.010","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T05:40:36Z","timestamp":1681450836000},"page":"390.e1-390.e17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Heterogeneity of BCG unresponsive bladder cancer clinical trials limits patients\u2019 access to novel therapeutics"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8119-7014","authenticated-orcid":false,"given":"Michael","family":"Chandra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Parwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"William E.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamal","family":"Pohar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debasish","family":"Sundi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2023.03.010_bib0001","first-page":"1","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer","volume":"196","author":"Chang","year":"2016","journal-title":"Am Urol Assoc (AUA) Guideline"},{"key":"10.1016\/j.urolonc.2023.03.010_bib0002","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on non\u2013muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.03.010_bib0003","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus calmette-guerin immunotherapy for recurrent Ta, T1, and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2023.03.010_bib0004","unstructured":"US Food and Drug Administration. BCG-unresponsive non-muscle invasive bladder cancer: developing drugs and biologics for treatment. Guidance for Industry. Available at: https:\/\/www.fda.gov\/media\/101468\/download. (Last accessed July 2020) (2018)."},{"key":"10.1016\/j.urolonc.2023.03.010_bib0005","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2023.03.010_bib0006","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2023.03.010_bib0007","first-page":"139","article-title":"Current Clinical Trials in Non-Muscle Invasive Bladder Cancer (NIMBC)","volume":"176","author":"Siddiqui","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2023.03.010_bib0008","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.urolonc.2021.05.015","article-title":"Non-muscle-invasive bladder cancer: An overview of potential new treatment options","volume":"39","author":"Shore","year":"2021","journal-title":"Urol Oncol: Semin Origin Investig"},{"issue":"12","key":"10.1016\/j.urolonc.2023.03.010_bib0009","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11934-018-0852-6","article-title":"Current Clinical Trials in Non-muscle Invasive Bladder Cancer","volume":"19","author":"Nykopp","year":"2018","journal-title":"Curr Urol Rep"},{"issue":"12","key":"10.1016\/j.urolonc.2023.03.010_bib0010","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s11934-019-0952-y","article-title":"Current Clinical Trials in Non-muscle-Invasive Bladder Cancer: Heightened Need in an Era of Chronic BCG Shortage","volume":"20","author":"Packiam","year":"2019","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.urolonc.2023.03.010_bib0011","doi-asserted-by":"crossref","first-page":"204","DOI":"10.5489\/cuaj.6101","article-title":"Emerging intravesical therapies for the management of bacillus calmette-gu\u00e9rin (bcg)-unresponsive non-muscle-invasive bladder cancer: Charting a path forward","volume":"14","author":"Chehroudi","year":"2020","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.urolonc.2023.03.010_bib0012","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4111\/icu.20200602","article-title":"Emerging treatments for bacillus calmette\u2013 gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer","volume":"62","author":"Kim","year":"2021","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.urolonc.2023.03.010_bib0013","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/iju.14153","article-title":"Bacillus calmette\u2013gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer:its definition and future therapeutic strategies","volume":"27","author":"Kikuchi","year":"2020","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2023.03.010_bib0014","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1146\/annurev-pathol-012513-104703","article-title":"Origins of bladder cancer","volume":"11","author":"Czerniak","year":"2016","journal-title":"Ann Rev Pathol: Mech Dis"},{"key":"10.1016\/j.urolonc.2023.03.010_bib0015","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/ncb2956","article-title":"Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma","volume":"16","author":"Shin","year":"2014","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.urolonc.2023.03.010_bib0016","doi-asserted-by":"crossref","first-page":"333","DOI":"10.48083\/CKYL2827","article-title":"Systematic review and meta-analysis of response rates in BCG-unresponsive non\u2013muscle-invasive bladder cancer: a consensus statement from the international bladder cancer group","volume":"3","author":"Rose","year":"2022","journal-title":"Soci\u00e9t\u00e9 Internationale d'Urologie J"},{"issue":"7","key":"10.1016\/j.urolonc.2023.03.010_bib0017","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.urolonc.2018.10.015","article-title":"Mutational landscape of non-muscle-invasive bladder cancer","volume":"40","author":"Hurst","year":"2022","journal-title":"Urol Oncol: Semin Orig Investig"},{"issue":"1","key":"10.1016\/j.urolonc.2023.03.010_bib0018","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","article-title":"An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer","volume":"12","author":"Lindskrog","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.urolonc.2023.03.010_bib0019","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00428-020-02808-6","article-title":"pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging","volume":"477","author":"Raspollini","year":"2020","journal-title":"Virchows Arch"},{"key":"10.1016\/j.urolonc.2023.03.010_bib0020","first-page":"7374","article-title":"Grading variability of urothelial carcinoma: Experience from a single academic medical center","volume":"21","author":"Lee","year":"2014","journal-title":"Can J Urol"},{"key":"10.1016\/j.urolonc.2023.03.010_bib0021","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/PAI.0000000000000401","article-title":"Flat Urothelial Lesions with Atypia: Interobserver Concordance and Added Value of Immunohistochemical Profiling","volume":"26","author":"Lawless","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.urolonc.2023.03.010_bib0022","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2021.12.005","article-title":"International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Gu\u00e9rin\u2013exposed High-risk Non\u2013muscle-invasive Bladder Cancer","volume":"82","author":"Roumigui\u00e9","year":"2022","journal-title":"Eur Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143923000947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143923000947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:28:27Z","timestamp":1761042507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143923000947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1078143923000947"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2023.03.010","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heterogeneity of BCG unresponsive bladder cancer clinical trials limits patients\u2019 access to novel therapeutics","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2023.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}